

SUPPLEMENTARY MATERIAL

Survival in a Contemporary, Real-World, Matched Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated vs Not Treated with Tafamidis

Fabian aus dem Siepen¹, Angela Dispenzieri², Mazen Hanna³, Martin Carlsson⁴, Pablo Garcia-Pavia⁵

¹University Hospital of Heidelberg, Heidelberg, Germany; ²Mayo Clinic, Rochester, MN, USA;

³Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA; ⁴Pfizer Inc, New York, NY, USA; ⁵Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, and Centro Nacional Investigaciones Cardiovasculares (CNIC), Madrid, Spain

Corresponding authors: Fabian aus dem Siepen; E-mail: Fabian.Siepen@med.uni-heidelberg.de

Table S1 Heart failure medications prior to tafamidis (treated patients) or prior to enrollment (untreated patients)

Indication, <i>n</i> (%) Category, <i>n</i> (%)	Treated (<i>n</i> = 283)	Untreated (<i>n</i> = 283)
Any concomitant heart failure medication	155 (54.8)	105 (37.1)
Agents acting on the renin-angiotensin system	30 (10.6)	0
Ace inhibitors, plain	13 (4.6)	0
Angiotensin II receptor blockers, combinations	5 (1.8)	0
Angiotensin II receptor blockers, plain	13 (4.6)	0
Beta blocking agents	26 (9.2)	0
Beta blocking agents	26 (9.2)	0
Cardiovascular disease	143 (50.5)	105 (37.1)
ACE inhibitors	14 (4.9)	32 (11.3)
Aldosterone antagonists and other potassium-sparing agents	20 (7.1)	0
Angiotensin II receptor antagonists	23 (8.1)	30 (10.6)
Beta blockers	42 (14.8)	63 (22.3)
Diuretics	66 (23.3)	99 (35.0)
High-ceiling diuretics	53 (18.7)	0
Low-ceiling diuretics excluding thiazides	4 (1.4)	0
Low-ceiling diuretics, thiazides	4 (1.4)	0


ACE angiotensin-converting enzyme.

Table S2 Heart failure medications after tafamidis initiation (treated) or after enrollment (untreated)

Indication, <i>n</i> (%) Category, <i>n</i> (%)	Treated (<i>n</i> = 283)	Untreated (<i>n</i> = 283)
Any concomitant heart failure medication	51 (18.0)	8 (2.8)
Agents acting on the renin-angiotensin system	7 (2.5)	0
Ace inhibitors, plain	5 (1.8)	0
Angiotensin II receptor blockers, combinations	1 (0.4)	0
Angiotensin II receptor blockers, plain	4 (1.4)	0
Beta blocking agents	14 (4.9)	0
Beta blocking agents	14 (4.9)	0
Cardiovascular disease	40 (14.1)	8 (2.8)
ACE inhibitors	2 (0.7)	3 (1.1)
Aldosterone antagonists and other potassium-sparing agents	11 (3.9)	0
Angiotensin II receptor antagonists	0	1 (0.4)
Beta blockers	5 (1.8)	3 (1.1)
Diuretics	13 (4.6)	3 (1.1)
High-ceiling diuretics	13 (4.6)	0
Low-ceiling diuretics excluding thiazides	3 (1.1)	0
Low-ceiling diuretics, thiazides	1 (0.4)	0
Diuretics	1 (0.4)	0
Other diuretics	1 (0.4)	0


ACE angiotensin-converting enzyme.

Fig. S1. Kaplan-Meier plot of overall survival in treated and untreated patients in NAC stage I




NAC National Amyloidosis Centre, OS overall survival.

Fig. S2. Kaplan-Meier plot of overall survival in treated and untreated patients in NAC stage II




NAC National Amyloidosis Centre, OS overall survival.

Fig. S3. Kaplan-Meier plot of overall survival in treated and untreated patients in NAC stage III



NAC National Amyloidosis Centre, OS overall survival.

Fig. S4. Kaplan-Meier plot of overall survival in treated and untreated patients with ATTRwt-CM



ATTRwt-CM wild-type transthyretin amyloid cardiomyopathy, OS overall survival.